THE BASIC PRINCIPLES OF TRASTUZUMAB DERUXTECAN T-DXD

One of the more underneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) claimed the lack of PTEN was noticed in 36% of HER2-optimistic Main breast tumor specimens from individuals with stage IV disorder. Moreover, they also showed that clients with PTEN-deficient tumors experienced remarkabl